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Context: Safety concerns have been raised regarding premature mortality, diabetes, neoplasia, and
cerebrovascular disease in association with GH therapy.
Objective: To assess incidence of key safety outcomes.
Design: Prospective, multinational, observational study (1999 to 2015).
Setting: A total of 22,311 GH-treated children from 827 investigative sites in 30 countries.
Patients: Children with growth disorders.
Interventions: GH treatment.
Main outcomemeasures: Standardized mortality ratio (SMR) and standardized incidence ratio (SIR)
with 95% CIs for mortality, diabetes, and primary cancer using general population registries.
Results: Predominant short stature diagnoses were GH deficiency (63%), idiopathic short stature
(13%), and Turner syndrome (8%), with mean 6 SD follow-up of 4.2 6 3.2 years (;92,000 person-
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pathic short stature; KIGS, Pfizer International Growth Study; NCGS, National
Cooperative Growth Study; OGHD, organic growth hormone deficiency; PY, person-year;
SAE, serious AE; SAGhE, Safety and Appropriateness of Growth hormone treatments in
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second neoplasm; T2DM, type 2 diabetes mellitus; TEAE, treatment-emergent AE; TS,
Turner syndrome.
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years [PY]). Forty-two deaths occurred in patients with follow-up, with an SMR (95% CI) of 0.61
(0.44, 0.82); the SMRwas elevated for patients with cancer-related organic GH deficiency [5.87 (3.21,
9.85)]. Based on 18 cases, type 2 diabetes mellitus (T2DM) risk was elevated [SIR: 3.77 (2.24, 5.96)],
but 72% had risk factors. In patients without cancer history, 14 primary cancers were observed [SIR:
0.71 (0.39, 1.20)]. Second neoplasms occurred in 31 of 622 cancer survivors [5.0%; 10.7 (7.5, 15.2)
cases/1000 PY] and intracranial tumor recurrences in 67 of 823 tumor survivors [8.1%; 16.9 (13.3,
21.5) cases/1000 PY]. All three hemorrhagic stroke cases had risk factors.
Conclusions: GeNeSIS (Genetics and Neuroendocrinology of Short Stature International Study) data
support the favorable safety profile of pediatric GH treatment. Overall risk of death or primary
cancer was not elevated in GH-treated children, and no hemorrhagic strokes occurred in patients
without risk factors. T2DM incidencewas elevated comparedwith the general population, butmost
cases had diabetes risk factors. (J Clin Endocrinol Metab 104: 379–389, 2019)
Pediatric GH treatment is approved for several con-ditions that result in short stature and/or growth
failure. Although the most frequent diagnosis is growth
hormone deficiency (GHD), other currently approved
indications include Turner syndrome (TS), short stature
homeobox-containing gene (SHOX) deficiency (SHOX-
D), Noonan syndrome, Prader-Willi syndrome, growth
failure associated with chronic renal insufficiency (CRI),
short stature in children born small for gestational age
(SGA) who fail to demonstrate catch-up growth by age 2
to 4 years, and idiopathic short stature (ISS). GH therapy
is generally considered safe, and serious adverse reactions
are infrequent (1–3). However, long-standing concerns
exist regarding a potential association between GH
treatment and the development or recurrence of neo-
plasms (4–8) and the effect on glucose homeostasis,
including development of type 2 diabetes mellitus
(T2DM) (9). More recently, data from the French co-
hort of the Safety and Appropriateness of Growth
hormone treatments in Europe (SAGhE) study raised
concerns for premature mortality (10) and intracranial
hemorrhage (11) in young adults treated with GH during
childhood.
In 1999, GeNeSIS (the Genetics and Neuroendocri-
nology of Short Stature International Study) was
implemented to monitor the safety and effectiveness of
GH in pediatric patients. Because rare outcomes are
unlikely to be observed in numbers appropriate for
statistical analysis in clinical trials, large postmarketing
studies, such as GeNeSIS, have been critical in estab-
lishing the GH safety profile. The primary safety ob-
jectives of GeNeSIS were to determine the incidence of
T2DM and primary cancer in GH-treated children.
Secondary objectives included characterization of neo-
plastic disease, especially neoplasm recurrence/progression
or second neoplasm (SN) development. In response to the
concerns raised by the French SAGhE findings (10, 11),




Patient data were collected in the prospective, multinational,
open-label, GeNeSIS observational program (ClinicalTrials.
gov: NCT01088412) for GH-treated pediatric patients; in
addition, non‒GH-treated patients with a history of neoplasia
or SHOX-deficient diagnosis were allowed. All investigational
and treatment decisions were at the discretion of the in-
vestigator, and no specific tests or procedures were required
before or during study participation.
Reporting of all adverse events (AEs) was required, irre-
spective of whether a causal relationship with GH was sus-
pected. The study was approved by local ethics committees and
was conducted according to the principles of the Declaration of
Helsinki, and all applicable country-specific regulatory re-
quirements were followed. Written parental (or guardian)
consent for data collection, electronic processing, and publi-
cation was provided in accordance with national requirements.
At study closure (data received from March 1999 to Sep-
tember 2015), enrollment had reached 22,845 patients from
827 sites in 30 countries (Supplemental Table 1). Of these,
22,311 patients were treated with GH, 457 were untreated, and
77 had unknown treatment status (Fig. 1). Different pop-
ulations analyzed included the Safety Population (date of birth/
GH treatment status available; N = 22,294), the Safety Pop-
ulation with at least one follow-up visit (N = 21,178), the Safety
Population with at least one follow-up visit and no previous
cancer (N = 20,556), and the Safety Population with baseline
height SD score available (N = 20,363).
Ascertainment of patient histories and
incident cases
Serious AEs (SAEs) that resulted in death, hospitalization,
persistent or major disability, or congenital abnormality in
offspring or that the investigator considered life-threatening
or major were assessed in the overall Safety Population.
Treatment-emergent AEs (TEAEs), which first occurred or
worsened in severity after GH therapy, were assessed in patients
who had at least one postbaseline follow-up visit. All AEs were
categorized according to theMedical Dictionary for Regulatory
Activities version 18.1.
Treatment-group comparisonwas inappropriate because the
small untreated group was represented primarily by patients
with a history of neoplasm or SHOX-D. For outcomes of death,
diabetes, and primary cancer, incidence was compared with
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rates in general population registries, with calculation of
standardized mortality ratios (SMRs) and standardized in-
cidence ratios (SIRs). Previous history and incident cases of
neoplasia during the study were ascertained by detailed review
of study database modules (12), including historical diagnoses,
disease-specific check boxes at each study visit, AEs/preexisting
conditions, and the Neoplasia Substudy (designed to follow up
on the course and treatment of neoplastic disease), with cross-
reference to SAE reports in the sponsor’s pharmacovigilance
database. Historical factors and causes of death were ascer-
tained using the same information sources, with case-specific
details reported previously (13). Histories and incident cases
related to abnormal glucose metabolism were ascertained es-
sentially as described for neoplasia and in a previous interim
analysis (14), with information from a variety of data sources
prioritized according to the scheme presented as Supplemental
Fig. 1 and assessment against standard diagnostic criteria (15).
Statistics
Analyses were conducted using SAS® 9.1. (SAS Institute Inc.,
Cary, NC) SMRs/SIRs and associated 95% CIs for mortality,
diabetes, and primary cancer were determined by country as the
ratio between the number of cases observed in GeNeSIS and the
expected number of incident cases from general population
registries, chosen on the basis of the availability of country-
specific data, age-range stratification, and contemporaneous-
ness with the period of GeNeSIS data collection. For mortality
statistics, sex-, age-, and calendar year‒specific data from the
Centers for Disease Control and Prevention (16) were used for
the United States and national or regional data from the World
Health Organization (17) were used for all other countries. For
diabetes, age-specific and race-specific data (2002 to 2005)
from the US SEARCH for Diabetes in Youth Study (18) were
used for comparison with all GeNeSIS countries because, to our
knowledge, they provide the best reference population for US
patients and a finer stratification of ages than pediatric diabetes
reference data from countries outside the United States. For
cancer rates, sex-, race-, age-, and calendar year‒specific data
from the Surveillance, Epidemiology, and End Results Program
(19) were used for the United States, and country-, sex-, and
age-specific 2012 data fromGLOBOCAN (20) were used for all
other countries. Country-specific SIRs/SMRs were calculated
from the sum of the available sex-, race/ethnicity-, age-, and
calendar year‒specific strata and overall from aggregation of
the country-specific data. The observed number of cases was
assumed to follow a Poisson distribution, and 95% CIs were
calculated using an exact method (21).
For all outcomes except diabetes, follow-up time per patient
was calculated from the date of first GH dose in GeNeSIS until
the date of the last contact (the latest of last follow-up visit,
study summary date, cancer onset date, or date of death). For
diabetes, follow-up time was calculated from the date of first
GH dose because accurate capture of cases that occurred
prestudy but after GH initiation was possible.
Results
Patient demographics
Of the 22,311 GH-treated patients, the most common
diagnostic group was GHD (63%), with the majority
having idiopathic GHD (IGHD; 79%). Of patients with
organic GHD (OGHD; 21%), the majority had disease
due to congenital causes (64%) such as abnormalities in
Figure 1. GeNeSIS patient disposition and main analysis populations.
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pituitary development. GHD due to acquired causes such
as an intracranial tumor and/or its treatment accounted
for 36%; the most common intracranial tumors were
craniopharyngiomas (N = 271) andmedulloblastomas (N=
218). The most common non-GHD causes of short stature
were ISS (13%), TS (8%), and being born SGA (6%).
Baseline characteristics and GH treatment parameters
for GH-treated patients are shown in Table 1. For all
diagnostic groups combined, 60% were male, mean age
at GH initiationwas 9.7 years, and age at study entry was
almost 1 year later (10.5 years), reflecting patients who
began GH therapy before study enrollment (;one-third
of the study population). Mean duration of follow-up in
the study was 4.2 years, whereas mean duration of
treatment was 4.9 years, providing ;92,000 person-
years (PY) of follow-up in the study and ;104,000 PY
of GH exposure.
General safety outcomes
Table 2 summarizes patients assessed for incidence of
key events, cases observed during GeNeSIS, and crude
incidence rates. Details on specific outcomes are provided
in subsequent subsections. Of the 22,294 patients in the
Safety Population, SAEs were reported for 567 (2.5%),
with 82 (14.5%) assessed as causally related to GH
(Supplemental Table 2). The most prevalent SAEs typi-
cally involved childhood infections and conditions as-
sociated with short stature diagnoses that may evolve
during GH treatment. However, the second-most prev-
alent SAE was craniopharyngioma with 20 cases, the
majority being recurrences. The most prevalent TEAEs
were, in general, common childhood ailments, conditions
associated with underlying diagnoses, or events pre-
viously associated with GH exposure. Overall, 6365
patients (30%; Safety Population with at least one
follow-up visit) had at least one TEAE during the study
(Table 3), with the highest rate in patients with CRI
(49%) and OGHD (47%). With a total of 16,135 sep-
arate event episodes, the overall crude incidence rate of
TEAE was 175.3/1000 PY.
Mortality
At study closure, 51 deaths were reported; 45 occurred
in 22,311 GH-treated patients and six in 457 untreated
patients. On the basis of 42 deaths in 21,106 patients
eligible for inclusion in the SMR calculation (mean6 SD
follow-up of 4.3 6 3.1 years), the crude mortality rate
(95% CI) for all-cause mortality for GH-treated patients
across all diagnoses was 0.46 (0.33, 0.62)/1000 PY, and
the overall SMR (95% CI) was 0.61 (0.44, 0.82). The
SMR calculation was repeated for patients who had $4
years of follow-up or who died at any time during the
study (N = 9504), and the SMR was 0.81 (0.58, 1.10)
with a mean follow-up of 7.1 6 2.6 years. The only
diagnostic subgroup with a statistically significantly el-
evated SMR was the OGHD group as a result of








Age (y) Height SDS
Height SDS 2 Target





20,363 40/60 9.7 6 3.8 8.5 6 3.8 22.5 6 1.0 22.0 6 1.2 20.4 6 1.7 7.6 (4.4, 12.1) 0.27 6 0.10
12,734 33/67 9.7 6 3.9 8.3 6 3.8 22.4 6 1.1 22.0 6 1.2 20.3 6 1.6 6.3 (3.6, 9.1) 0.24 6 0.10
10,189 33/67 10.1 6 3.6 8.5 6 3.7 22.4 6 1.0 21.9 6 1.1 20.4 6 1.6 6.8 (4.4, 9.5) 0.25 6 0.10
2508 35/65 8.2 6 4.6 7.3 6 4.2 22.4 6 1.5 22.4 6 1.5 0.0 6 1.9 2.9 (1.0, 6.0) 0.23 6 0.09
2657 28/72 11.3 6 3.1 10.1 6 3.2 22.4 6 0.8 21.9 6 1.0 20.6 6 1.4 15.0 (11.6, 20.0) 0.33 6 0.09
1209 45/55 8.2 6 3.6 7.1 6 3.7 22.7 6 0.9 22.1 6 1.2 21.4 6 1.8 11.6 (7.8, 17.5) 0.24 6 0.10
1712 99/1e 8.8 6 3.8 8.2 6 3.4 22.6 6 0.9 22.6 6 1.1 0.3 6 1.5 11.0 (6.6, 16.8) 0.32 6 0.09
547 58/42 9.3 6 3.2 8.7 6 3.2 22.3 6 0.8 21.4 6 1.0 0.1 6 1.4 11.6 (8.0, 17.5) 0.30 6 0.09
82 33/67 8.4 6 3.9 6.7 6 3.6 22.6 6 1.0 22.3 6 1.0 20.6 6 1.9 15.2 (11.9, 23.7) 0.30 6 0.10
1124 40/60 9.4 6 4.0 8.8 6 3.8 22.7 6 1.3 22.4 6 1.5 20.4 6 2.0 9.8 (6.0, 16.1) 0.28 6 0.10
Data are presented as mean 6 SD unless stated otherwise.
Abbreviations: BMI, body mass index; F, female; M, male; Max, maximum; N, number; SDS, standard deviation score.
aMaximum N, lower for certain variables.
bMedian (Q1, Q3); N (%) with reported GH peak: GHD, 9945 (78); ISS, 2032 (76); SGA, 586 (48); TS, 317 (19); SHOX-D, 175 (32); CRI, 16 (20); and Other,
676 (60).
cDose at initiation of GH therapy.
dIncludes 298 patients with unknown diagnosis.
eUnclear whether male patients with reported TS diagnosis reflect data entry error or so-called “male TS” (i.e., Noonan syndrome).
fShort stature–related diagnoses not in the previous categories, including genetic and cytogenetic conditions, clinical syndromes, skeletal dysplasias, and
other non-GHD disturbances of the GH/IGF-I axis.
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malignant neoplasm [14 deaths; SMRs of 5.87 (3.21,
9.85) overall and 7.16 (3.91, 12.01) for the 4-year
follow-up population]. A comparison of mortality in-
cidence in GeNeSIS using aggregated regional World
HealthOrganization general population rates (with more
granular pediatric age ranges) but with slightly lower
SMRs were recently published (12).
Diabetes and abnormal glucose metabolism
A total of 38 incident cases of diabetes mellitus (19
type 1, 18 type 2, and 1 case with type not specified) were
reported in a cohort of 21,448 patients eligible for
analysis, with mean 6 SD follow-up from start of GH
therapy of 5.0 6 3.5 years (107,101 PY). Of the 18
reported cases of T2DM, two cases occurred within










Death All 21,178 42 (0.20)b 0.46 (0.34–0.62)
Stroke (all) All 21,178 16 (0.08) 0.17 (0.11–0.28)
Stroke (unknown) All 21,178 3 (0.01) 0.03 (0.01–0.10)
Hemorrhagic All 21,178 3 (0.01) 0.03 (0.01–0.10)
Ischemic All 21,178 10 (0.05) 0.11 (0.06–0.20)
Type 2 diabetes mellitus All 21,178 18 (0.08) 0.20 (0.12–0.31)
Primary cancer No cancer history 20,556 14 (0.07) 0.16 (0.09–0.27)
Second neoplasm History of cancer 622 31 (4.98) 10.69 (7.51–15.19)
ICT recurrence History of ICT 823 67 (8.14) 16.90 (13.30–21.47)
CP recurrence History of CP 271 37 (13.65) 26.32 (19.07–36.32)
MB recurrence History of MB 218 6 (2.75) 5.69 (2.09–12.40)
Abbreviations: CP, craniopharyngioma; ICT, intracranial tumor; MB, medulloblastoma; N, number.
aReflects first episode of event per patient (where relevant).
bThree additional deaths were reported but not included in calculations because of lack of on-study follow-up visit.
Table 3. Frequency of TEAEs byMedDRA Preferred Term Occurring in ‡1.0% of All GH-Treated Patients, Split
by Main Short Stature Diagnosis
Alla GHD IGHD OGHDb ISS TSc SHOX-D SGA CRId Other
N, % 21,178 13,329 10,450 2831 2686 1791 564 1227 77 1169
Patients with no
TEAE
14,813 9572 8200 1500 2031 979 420 824 39 668
Patients with $1
TEAE
6365 (30.1) 3757 (28.2) 2250 (21.5) 1331 (47.0) 655 (24.4) 812 (45.3) 144 (25.5) 403 (32.8) 38 (49.4) 501 (42.9)
By MedDRA Preferred
Terme:
Headache 607 (2.9) 378 (2.8) 201 (1.9) 176 (6.2) 76 (2.8) 62 (3.5) 10 (1.8) 36 (2.9) 2 (2.6) 37 (3.2)
Hypothyroidism 598 (2.8) 430 (3.2) 224 (2.1) 206 (7.3) 31 (1.2) 75 (4.2) 5 (0.9) 23 (1.9) — 34 (2.9)
Scoliosis 424 (2.0) 222 (1.7) 132 (1.3) 90 (3.2) 41 (1.5) 81 (4.5) 7 (1.2) 20 (1.6) 3 (3.9) 43 (3.7)
ADHD 390 (1.8) 216 (1.6) 157 (1.5) 58 (2.0) 75 (2.8) 37 (2.1) 4 (0.7) 23 (1.9) 2 (2.6) 31 (2.7)
Arthralgia 381 (1.8) 214 (1.6) 147 (1.4) 66 (2.3) 50 (1.9) 49 (2.7) 16 (2.8) 22 (1.8) — 23 (2.0)
Secondary
hypothyroidism
321 (1.5) 264 (2.0) 95 (0.9) 169 (6.0) 16 (0.6) 15 (0.8) 1 (0.2) — — 20 (1.7)
Precocious puberty 264 (1.2) 141 (1.1) 86 (0.8) 54 (1.9) 34 (1.3) 9 (0.5) 17 (3.0) 43 (3.5) — 18 (1.5)
Otitis media 202 (1.0) 90 (0.7) 39 (0.4) 51 (1.8) 11 (0.4) 69 (3.9) 1 (0.2) 10 (0.8) 1 (1.3) 19 (1.6)
URTI 201 (1.0) 121 (0.9) 50 (0.5) 71 (2.5) 15 (0.6) 42 (2.3) 2 (0.4) 5 (0.4) 1 (1.3) 15 (1.3)
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; MedDRA, Medical Dictionary for Regulatory Activities; N, number; URTI, upper respiratory
tract infection.
a Includes 335 patients with unknown diagnostic group.
bAdditional preferred terms with frequency $2.0% for OGHD [N (%)] are delayed puberty, 85 (3.0); adrenal insufficiency, 79 (2.8); hypogonadism, 74
(2.6); secondary hypogonadism, 70 (2.5); pyrexia, 66 (2.3); vomiting, 64 (2.3); hypopituitarism, 66 (2.3); constipation, 58 (2.0); and gastroenteritis, 58
(2.0).
cAdditional preferred terms with frequency$1.0% for TS [N (%)] are ovarian failure, 66 (3.7); melanocytic naevus, 62 (3.5); primary hypothyroidism, 41
(2.3); autoimmune thyroiditis, 34 (1.9); delayed puberty, 33 (1.8); ear infection, 26 (1.5); aortic dilation, 25 (1.4); hypogonadism, 25 (1.4); hypertension,
24 (1.3); bicuspid aortic valve, 21 (1.2); vitamin D deficiency, 20 (1.1); pharyngitis streptococcal, 19 (1.1); deafness, 18 (1.0); and vomiting, 18 (1.0).
dAdditional preferred terms with frequency $2.0% for CRI [N (%)] are renal transplant, 9 (11.7); anemia, 3 (3.9); chronic kidney disease, 3 (3.9);
thrombocytopenia, 2 (2.6); urinary tract infection, 2 (2.6); bronchitis, 2 (2.6); hypertension, 2 (2.6); primary hypothyroidism, 2 (2.6); renal impairment, 2
(2.6); and vomiting, 2 (2.6).
e Individual TEAEs are summarized by case, not by patient. A patient may have .1 TEAE.
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1 year of start of GH therapy, nine cases between 1 and
4 years, and seven cases in patients with .4 years of GH
therapy. In addition, there were 75 reported cases of
other abnormal glucose metabolism conditions (in-
cluding 27 reports of impaired glucose tolerance, nine
reports of impaired fasting glucose, and cases of reported
insulin resistance, hyperglycemia, and hyperinsulinemia).
SIRs (95%CI) for all countries combined were calculated
as 0.92 (0.56, 1.44) for type 1 diabetes mellitus and 3.77
(2.24, 5.96) for T2DM (Table 4). Because the SEARCH
for Diabetes in Youth reference data are based on US
patients only, SIRs were calculated separately for only
patients from the United States: 1.08 (0.49, 2.05) for type
1 diabetes mellitus and 4.67 (2.13, 8.86) for T2DM
(Supplemental Table 3). For T2DM, the statistically
significantly elevated SIR observed for all diagnoses
combined appeared to be driven by girls with TS [three
cases; SIR (95% CI): 6.46 (1.33, 18.89)] and by patients
with OGHD [eight cases; SIR (95% CI): 9.35 (4.04,
18.43)]. The SIR for T2DM was not statistically signif-
icantly elevated for other short stature diagnoses
(Table 4); no cases of T2DM were observed during
GeNeSIS in patients with ISS or SHOX-D. Risk factors
for development of T2DMwere reported for 13 of the 18
incident cases (Table 4).
Primary cancers
Of the 20,187 patients without a history of malig-
nancy who were eligible for analysis, 12,734 (63%) had
GHD, of whom 10,413 (52%) had IGHD, 1804 (9%)
had OGHD due to congenital GHD, and 467 (2%) had
OGHD due to acquired causes (including craniophar-
yngioma and pilocytic astrocytoma). Other major di-
agnoses included ISS, 2579 (13%); TS, 1782 (9%); and
being born SGA, 1222 (6%). Baseline and treatment
characteristics of the cohort (all diagnoses combined) were
similar to those of the overall safety cohort (data not shown).
From ;89,000 PY of follow-up, 14 malignant pri-
mary neoplasms were identified, with a crude incidence
rate estimated at 15.8/100,000 PY and a mean age at
reported onset of cancer of 13.6 years. Of the 14 reported
cases of primary cancer, three cases occurred within
1 year of start of GH therapy, five cases between 1 and
4 years, and six cases in patients with .4 years of GH








Cases SIR (95% CI)
All 21,448c 107,101 Type 1 19 17.7 (10.7–27.7) 20.6 0.9 (0.6–1.4)
Type 2 18 16.8 (10.0–26.6) 4.8 3.8 (2.2–6.0)
GHD 13,507d 68,526 Type 1 10 14.6 (7.0–26.8) 13.2 0.8 (0.4–1.4)
Type 2 12e,f 17.5 (9.1–30.6) 3.1 3.9 (2.0–6.9)
IGHD 10,585 49,123 Type 1 4 8.1 (2.2–20.9) 9.4 0.4 (0.1–1.1)
Type 2 4e 8.1 (2.2–20.9 2.2 1.8 (0.5–4.7)
OGHD 2874 19,211 Type 1 6 31.2 (11.5–68.0) 3.7 1.6 (0.6–3.5)
Type 2 8f 41.6 (18.0–82.1) 0.9 9.4 (4.0–18.4)
TS 1815 10,423 Type 1 3 28.8 (5.9–84.1) 2.0 1.5 (0.3–4.4)
Type 2 3g 28.8 (5.9–84.1) 0.5 6.5 (1.3–18.9)
ISS 2645 11,019 Type 1 3 27.2 (5.6–79.6) 2.1 1.4 (0.3–4.1)
Type 2 0 0.0 (0.0–33.5) 0.5 0.0 (0.0–7.5)
SGA 1111 5689 Type 1 0 0.0 (0.0–64.9) 1.1 0.0 (0.0–3.4)
Type 2 2h 35.2 (4.3–127.0) 0.3 7.9 (1.0–28.5
Other 1488 7491 Type 1 3 40.1 (8.3–117.0) 1.4 2.1 (0.4–6.1)
Type 2 1i 13.4 (0.3–74.4) 0.3 3.0 (0.1–16.7)
Abbreviations: MELAS, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; N, number.
aAn additional case was reported for which type of diabetes was not defined as type 1 or type 2.
bAn additional seven cases were reported in patients with known underlying pathology causative for diabetes (cystic fibrosis‒related diabetes, two cases;
MELAS syndrome, two cases; and one case each of sideroblastic anemia, post pancreatic surgery, and steroid-induced diabetes); these events were not
included as cases for the SIR calculation.
cIncludes patients with SHOX-D, CRI, and unknown short stature‒related diagnoses who had no cases of incident diabetes.
dIncludes patients for whom type of GHD has not been specified.
eIncludes one patient with IGHD and risk factor of history of obesity.
fIncludes patients with OGHD and the following risk factors: childhood cancer survivors with GHD due to leukemia and irradiation (three patients), history
of craniopharyngioma and obesity (one patient), history of glioma and obesity (one patient), and preexisting insulin resistance (one patient with hy-
popituitarism due to PROP1 gene defect).
gPatients with TS considered at increased risk; one patient with preexisting impaired glucose tolerance.
hPatients with Russell-Silver syndrome (both patients) considered at increased risk.
iPatient with Prader-Willi syndrome and obesity.
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therapy. The SIR (95% CI) for primary cancers in GH-
treated patients was 0.71 (0.39, 1.20) for all countries
combined; no individual country had a significantly el-
evated SIR (Table 5).
Because lymphoma represented the most common
tumor type, the SIR (95% CI) was calculated separately
for lymphoma cases. The SIR for all countries combined
was 1.93 (0.63, 4.51), but for Germany specifically, with
four of the five cases, the SIR was statistically signifi-
cantly elevated (Table 5). Four of the 14 patients had a
defined predisposition to cancer (Table 5), whereas 10 of
the affected patients had no recorded specific risk factors
for malignancy; three of the cases were in patients with
syndromic short stature diagnoses (Russell-Silver syn-
drome and TS for two of the lymphoma cases and TS for
the Ewing sarcoma case).
Neoplasm recurrences
There were 85 reports of recurrences in 74 of 1087
(6.8%) GH-treated children with at least one follow-up
visit available and a history of previous neoplasm.
Multiple recurrences were reported for seven patients:
four with multiple craniopharyngioma recurrences (nine
reported episodes), one with medulloblastoma re-
currences (four episodes), one with optic glioma re-
currences (three episodes), and one with ovarian fibroma
recurrences (two episodes). There were 77 cases of in-
tracranial tumor recurrences in 67 of 823 patients
(8.1%), with craniopharyngioma recurrence being most
common (42 episodes in 37 patients), followed by re-
currence of astrocytoma (11 cases) and medulloblastoma
(nine episodes in six patients). Although direct com-
parison between treatment groups is not appropriate
because of inherent uncontrolled biases, for completeness
of the record, there were nine reports of recurrences in
nine of 148 untreated patients (6.1%), including four
astrocytoma recurrences.
SNs
Among 622 GH-treated survivors of childhood can-
cers, there were 34 reports of SNs in 31 patients (5.0%);
10 SNs were reported in nine of 114 untreated childhood
cancer survivors (7.9%). Supplemental Table 4 lists
details of all SNs recorded in GeNeSIS. As reported in the
Childhood Cancer Survivor Study (CCSS) (17) and in a
previously published analysis from GeNeSIS (22), the
most common SNs in GH-treated patients are menin-
giomas. All four patients who developed ameningioma in
the final GeNeSIS data set had reported cranial irradi-
ation as part of their treatment of primary disease. Ra-
diation therapy for the primary neoplasm was reported
for 25 of the 31 GH-treated patients with any SN.
Cerebrovascular disease
Sixteen patients were reported to have TEAEs of
nontraumatic cerebrovascular disease during GeNeSIS
Table 5. Primary Cancer Cases and Standardized Incidence Ratios in Patients Without Cancer History for All
Sites/Types of Cancer and Lymphomas Only
Countrya N PY Observed Cases Expected Cases SIR (95% CI)
All sites/types of cancer
Canada 710 3671 3b 1.05 2.87 (0.59–8.38)
France 1544 7876 3c 2.16 1.39 (0.29–4.07)
Germany 2580 14,825 5d 4.03 1.24 (0.40–2.89)
Japan 2230 7302 1e 0.99 1.01 (0.03–5.63)
USA 8734 33,957 2f 6.14 0.33 (0.04–1.18)
Overall 20,146 88,749 14g,h 19.62 0.71 (0.39–1.20)
Lymphomas only
France 1544 7876 1 0.24 4.21 (0.11–23.44)
Germany 2580 14,825 4 0.39 10.25 (2.79–26.25)
Overall 20,146 88,749 5 2.59 1.93 (0.63–4.51)
Abbreviation: N, number.
aCountries with no incident cases are not listed in the table but are included in the overall SIR.
bEwing sarcoma, osteochondroma, and pancreatic neuroendocrine tumor.
cGonadoblastoma, T-cell lymphoma, and rectal adenocarcinoma.
dB-cell lymphoma, Burkitt-like lymphoma, Burkitt lymphoma, lymphoma, and malignant schwannoma.
eGerminoma.
fGerm-cell tumor and skin cancer.
gSpecific risk factors reported: (i) recurrent neurofibromatosis and Gardner syndrome (case of rectal adenocarcinoma in a French patient, (ii) hamartomas
and neurofibromatosis (pancreatic neuroendocrine tumor in a Canadian patient, (iii) pilocytic astrocytoma (malignant schwannoma in a German patient),
and (iv) streak gonad of a French patient with 46,XY mixed gonadal dysgenesis (gonadoblastoma).
hThree cases were in patients with syndromic short stature diagnoses (two lymphomas in German patients with Russell-Silver syndrome and TS and the
Ewing sarcoma in a Canadian patient with TS).
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(Table 2). Three intracranial hemorrhages were reported
in GH-treated patients in the GeNeSIS database. The first
was a fatal stroke described as “intracranial hemor-
rhage” after a renal transplant in a patient with CRI. The
second was a case of “cerebral hemorrhage” in a patient
with a history of optic glioma and many cerebrovascular
anomalies. The third case was reported as “hemorrhage
into glioma” in a patient with a history of glioma, as-
trocytoma, and tumor resection. Supplemental Table 5
provides details of short stature diagnosis and risk factors
for all 16 cerebrovascular disease cases: 11 had a prior
intracranial tumor, one had Ewing sarcoma, one was the
previously described patient with CRI, and three patients
had IGHD.
Discussion
GeNeSIS was a large observational study of GH treat-
ment outcomes in children with short stature and/or
growth failure conducted over 16 years and enrolling
22,845 patients from 30 countries. Patient baseline
characteristics were consistent with those of a broad
population of pediatric GH users for age, sex, short
stature diagnoses, and GH dose. Therefore, the results
provide important real-world safety information from a
large cohort.
The reported AE rate in the final GeNeSIS database
(crude incidence of 175.3/1000 PY) appeared higher than
in other observational studies of pediatric GH use,
ranging from 5.6 to 103.1 per 1000 PY (23). However,
GeNeSIS and the Pfizer International Growth Study were
the only studies to require reporting of all AEs, irre-
spective of potential causality by GH. In agreement with
findings from the National Cooperative Growth Study
(NCGS) (2), the short stature diagnoses with the highest
AE and SAE incidences were CRI and OGHD because of
the severity of the underlying medical conditions.
During the 16-year duration of data collection in
GeNeSIS, a number of potential safety issues related to
the use of GH were raised and investigated. The French
SAGhE study reported an increased mortality rate in
young adults previously treated with GH during child-
hood for IGHD, ISS, and SGA (10). Although GeNeSIS is
not directly comparable to SAGhE, especially in length of
follow-up, the GeNeSIS data are reassuring, showing no
increased mortality rate during the study in the same
diagnostic groups, consistent with the SAGhE findings
from Belgium, The Netherlands, and Sweden (24) and a
recent assessment of mortality in Swedish GH-treated
patients (25).
With .100,000 PY of GH exposure, 18 cases of
T2DM were identified, representing an incidence rate of
16.8/100,000 PY. The final GeNeSIS incidence rate is
lower than the previously reported 29.3/100,000 PY rate
based on GeNeSIS data to September 2007 (13) and the
34.4/100,000 PY of GH treatment observed in the Pfizer
International Growth Study (KIGS) .15 years ago (9).
The incidence of T2DM across the whole study period
was increased compared with general population rates:
by 3.8-fold vs 6.5-fold in the earlier GeNeSIS analysis
(14) and 6.4-fold in the KIGS analysis (9). Increased risk
for diabetes appears largely confined to those with risk
factors (26); in GeNeSIS, 13 of the 18 patients with in-
cident cases of T2DM in the main analysis had risk
factors for diabetes. In particular, patients with OGHD
had the highest risk for T2DM when compared with the
general population, including three cases with increased
risk due to a history of leukemia irradiation (27) and one
with concomitant Prader-Willi syndrome. In the absence
of known diabetes risk factors, two recent studies
exhibited no effect of GH on the rate of diabetes or
negative effect on glucose homeostasis. The French
SAGhE study data indicated no difference in the prev-
alence of diabetes between GH-treated patients with
IGHD, ISS, or SGA and the general population (28).
Although no deterioration in glucose homeostasis or new
cases of diabetes were found in children with GHD in a
6-year follow-up study, a positive influence of GH/IGF-I
on islet b-cell secretory capacity (29) was observed. This
suggests that clinicians should focus efforts on lifestyle
interventions in GH-treated patients with T2DM risk
factors.
Concerns remain that GH treatment may be associ-
ated with primary cancer induction because of the mi-
togenic action of GH and high rates of specific cancer
types in patients with acromegaly. In comparison with
general population cancer registries, there appeared to be
no higher risk for all-sites primary cancers in GH-treated
patients in GeNeSIS, the same finding as in analyses of
patients without risk factors for malignancy from both
the KIGS and NCGS databases (2, 30). In addition, the
crude incidence rate of 15.8/100,000 PY in GeNeSIS was
similar to that from the KIGS: 16.4 cases/100,000 PY
(30). A recent report from the pan-European SAGhE
study (31) indicated no overall raised cancer-related
morbidity or mortality risk in patients with growth
failure without other major disease: SIR (95% CI) of
1.0 (0.6, 1.4) and SMR (95% CI) of 0.8 (0.4, 1.6). The
authors concluded that their results did not generally
support a carcinogenic effect of GH but the raised in-
cidence of bone and bladder cancers in GH-treated pa-
tients and Hodgkin lymphoma with increasing follow-up
required further investigation.
The most prevalent primary cancer type in GeNeSIS
was lymphoma, with an elevated but not statistically
significant overall SIR of 1.9 (0.6, 4.5). However, for
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Germany, with four of the five cases, the SIR was sta-
tistically significant at 10.3 (2.8, 26.3). Previously, an
SMR of 11.5 (1.4, 41.3) and an SIR of 2.3 (0.3, 8.5) were
reported for Hodgkin disease (two cases) in a cohort of
1848 cadaveric GH-treated patients (32). Of the GeN-
eSIS cases, at least three were non-Hodgkin type and the
remaining two cases were unknown. The small number
of cases hinders interpretation of such a finding, and
there is no explanation for an increased risk in Germany,
although two of the cases were in patients with syn-
dromic short stature diagnoses. Two recent literature
reviews found no association between GH therapy
during childhood in children without prior cancer or
known risk factors for developing cancer (8, 26). Patients
with risk factors for cancer development were included in
our analyses as long as they had not had previous cancer.
The genotype/phenotype of such patients must be taken
into account and the patients closely monitored for
neoplastic disease during GH treatment.
The recurrence rate (crude incidence per 1000 PY) for
intracranial tumors in GH-treated GeNeSIS patients was
8.1% (19.4%) overall, and 13.7% (29.9%) and 2.8%
(8.5%) for craniopharyngioma and medulloblastoma,
respectively. The GeNeSIS craniopharyngioma recur-
rence rate is broadly comparable to that in the litera-
ture, but rates of craniopharyngioma recurrence vary
depending on the extent of surgical resection, ranging
between 17% and 36% for gross total resection (8% to
10% when neuroradiologically confirmed) to between
43% and 67%, for partial resection (33). A retrospective
study of more than 500 medulloblastoma survivors di-
agnosed and treated between 1980 and 1993 found no
effect of GH treatment on risk of tumor recurrence (34).
Analyses of GH-treated survivors of childhood medul-
loblastoma followed up in the NCGS determined a
medulloblastoma recurrence rate of 7.2% (35), whereas
the KIGS database reported 92% relapse-free survival at
4.6 years (36). A number of older retrospective studies (6,
35, 37) and more recent meta-analyses (38, 39) indicated
that GH-treated patients with a history of intracranial
tumor had lower rates of recurrence than untreated
patients, but this likely reflects a selection bias, with those
at a lower risk for tumor recurrence more likely to receive
GH therapy. Nevertheless, according to data from many
study cohorts, including GeNeSIS, there appears to be no
evidence for increased risk of intracranial tumor re-
currence in children treated with GH.
The final results from GeNeSIS do not provide any
direct evidence supporting an increased risk of SNs in
GeNeSIS. However, a previous analysis of GeNeSIS (12)
concluded that the initial study findings were consistent
with early reports from the CCSS, which indicated that
GH therapy was associated with a higher relative risk of
SNs (6, 7). At the close of GeNeSIS, the percentage of
GH-treated survivors of childhood cancer who de-
veloped an SN was 5%, with a crude incidence of 12/
1000 PY. When the analysis was restricted to only those
patients with intracranial neoplasms, the percentage of
patients affected was 1.3%, with a crude incidence of 3/
1000 PY. Meningioma was among the most common
SNs in GH-treated patients in GeNeSIS; however, only
four cases were reported in three patients, and these
represented all of the observed intracranial SNs. The low
rate of intracranial SNs is therefore consistent with a
subsequent CCSS follow-up report based on an extended
length of surveillance, which did not show a statistically
significantly higher risk of secondary central nervous
system tumors among long-term survivors who had re-
ceived GH-therapy during childhood (40).
With three cases of hemorrhagic stroke in patients
with considerable risk factors, GeNeSIS data were not
consistent with the finding of increased risk for in-
tracranial hemorrhage in the French SAGhE cohort (11).
Similarly, only one intracranial hemorrhage and two
unspecified stroke cases were identified in 1024 adult
patients with childhood-onset GHD who received GH as
children and were subsequently followed up in the Hy-
popituitary Control and Complications Study; all three
patients had underlying risk factors: two patients with a
history of brain tumor, surgery, and radiotherapy and
one with a history of meningocele surgery (41).
Our data should be interpreted in light of certain
limitations. Patient recruitment was solely at the dis-
cretion of the investigator; although selection bias is a
possibility, it may be mitigated by recruitment reflecting
real-world prescribing for a large number of patients. In
addition, because GeNeSIS was an observational study,
reporting of cases was dependent on investigators from
30 countries, typically without sponsor monitoring of
patient medical records. Although a potential under-
reporting of event cases must be considered, multiple
data fields from the GeNeSIS and corporate pharma-
covigilance databases were used to ascertain cases, and
investigators were reminded of the importance of
AE reporting throughout study participation. Similarly,
GeNeSIS data were compared with general population
registries from countries with varied quality of health
care systems and may be subject to other biases. The
average follow-up time in GeNeSIS was relatively short
(mean, 4.2 years for GH-treated patients) for consider-
ation of conditions such as T2DM and cancer and only
during childhood GH treatment, with the possibility
that a higher risk may be revealed with longer GH
treatment and/or follow-up. However, it is noteworthy
that ;60% of both T2DM and primary cancer cases in
GeNeSIS occurred within 4 years of the start of GH
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therapy. The period of follow-up marks a critical dif-
ference between GeNeSIS and analyses from the CCSS
and SAGhE cohorts, where follow-up extended past the
period of pediatric GH treatment; therefore, average
follow-up per patient was much longer.
In conclusion, the results of the large GeNeSIS ob-
servational program indicate that the benefit-risk profile
of GH remains favorable, although we acknowledge that
average follow-up time within the study was relatively
short. Compared with general population registries, GH-
treated patients in GeNeSIS had no increased risk of early
mortality, except patients with previous malignancy, and
no increased risk for all-cause primary cancers. GH-
treated patients in GeNeSIS did have an increased risk
for T2DM, but most of these patients had diabetes risk
factors. In addition, no cases of hemorrhagic stroke were
observed in patients without significant risk factors.
Although the GeNeSIS data are reassuring overall, spe-
cific safety findings emphasize the need to monitor GH-
treated patients for abnormalities in glucose metabolism
and those with a history of previous neoplasm and ir-
radiation for development of subsequent neoplasms.
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